首页> 美国卫生研究院文献>Oncology Letters >Disappearance of bone metastases in chemotherapy-resistant gastric cancer treated with antigen peptide-pulsed dendritic cell-activated cytotoxic T lymphocyte immunotherapy: A case report
【2h】

Disappearance of bone metastases in chemotherapy-resistant gastric cancer treated with antigen peptide-pulsed dendritic cell-activated cytotoxic T lymphocyte immunotherapy: A case report

机译:抗原肽脉冲树突状细胞激活的细胞毒性T淋巴细胞免疫疗法治疗的化疗耐药性胃癌骨转移的消失:一例报告

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。
获取外文期刊封面目录资料

摘要

The adoptive transfer of cytotoxic T lymphocytes (CTLs) stimulated by specific tumor antigen peptide-pulsed dendritic cells (DCs) is one of the most promising immunotherapeutic strategies currently available for patients with gastric cancer (GC). The present case report describes a patient with chemotherapy-resistant stage IV GC with multiple bone metastases, who had been treated with antigen peptide-pulsed DC-CTLs. DCs and CTLs were transfused into the patient subcutaneously and intravenously with simultaneous oral administration of low-dose cyclophosphamide. Following 3 cycles of combination therapy, marked remission regarding the number of metastatic bone lesions was achieved, confirmed by the use of enhanced computerized tomography, computerized tomography and magnetic resonance imaging. After 1 year, 8 cycles of adoptive immunotherapy were administered, and a further decrease in the number of metastatic bone lesions was observed in addition to a marked improvement in the patient's quality of life. Therefore, personalized antigen peptide-pulsed DC-CTLs combined with oral administration of low-dose cyclophosphamide may serve as a promising anticancer therapy to eradicate tumor cells, and therefore this approach is recommended for future cases of a similar nature.
机译:由特定的肿瘤抗原肽脉冲树突状细胞(DCs)刺激的细胞毒性T淋巴细胞(CTL)的过继转移是目前可用于胃癌(GC)患者的最有希望的免疫治疗策略之一。本病例报告描述了患有化疗耐药的IV期GC并伴有多处骨转移的患者,该患者接受了抗原肽脉冲DC-CTL的治疗。在同时口服低剂量环磷酰胺的同时,将DC和CTL皮下和静脉内输注到患者体内。经过3个周期的联合治疗,通过使用增强型计算机断层扫描,计算机断层扫描和磁共振成像技术,证实了有关转移性骨病变数目的明显缓解。 1年后,进行了8个周期的过继免疫疗法,除了明显改善了患者的生活质量外,还观察到转移性骨病变的数量进一步减少。因此,个性化的抗原肽脉冲的DC-CTL结合口服低剂量的环磷酰胺可能是根除肿瘤细胞的有前途的抗癌治疗方法,因此,该方法建议用于类似性质的未来病例。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号